Piper Sandler reiterates Boston Scientific stock rating on survey By Investing.com

Piper Sandler reiterated an Overweight rating and $90 price target on Boston Scientific, implying meaningful upside versus the current $56.50 share price. The firm said the recent pullback looks overdone despite some physician caution around Watchman stand-alone cases and CHAMPION data, with surveyed doctors projecting 7% annual LAA closure growth through 2028. The article also highlights Q1 revenue of $5.2B (+11.6% reported, +9.4% organic), EPS of $0.80, lowered full-year guidance, and a new $2B buyback program.

Analysis

BSX looks less like a broken growth story and more like a de-rated platform waiting for sentiment to stabilize. The key second-order effect is that when a category leader trades near its lows while still compounding mid/high-single digits, the market is usually pricing a permanent slope break that often does not materialize unless reimbursement or guidelines move against it. In that setup, near-term price action becomes more about positioning and analyst downgrades than fundamentals, which creates a tradable dislocation if the next print simply confirms intact demand.

The softer Watchman commentary is important, but the larger implication is that TAM expansion is being pushed out, not eliminated. That means the competitive battleground shifts from “new indication expansion” to share defense and procedure mix within the existing eligible population, which tends to favor the incumbent with the deepest training, reimbursement familiarity, and installed physician habits. Competitors trying to win low-risk patients may find the bar higher than the street assumes, because physician adoption depends more on guideline cover than on marginal data updates.

The real catalyst stack is asymmetrical over the next 1-2 quarters: a single clean quarter with no further guidance cuts can force a re-rating, while any evidence of stabilization in procedure volumes should squeeze the recent short/underweight crowd. The risk case is that lowered guidance was an early signal of broader slowing across adjacent device categories, which would turn this into a multiple trap rather than a value opportunity. I would watch for any sign that capital return plus organic growth can re-anchor investor expectations; buybacks help defend the downside, but only if volume growth does not deteriorate further.

Key Decisions for Investors

• Go long BSX on weakness over the next 1-3 weeks with a 3-6 month horizon; entry is most attractive near current valuation extremes, targeting a re-rating toward prior trading bands if growth stabilizes. Risk/reward is roughly 2:1 if the stock mean-reverts even modestly, but the thesis breaks if another guidance reset hits.
• Use BSX call spreads rather than outright shares for a 2-quarter catalyst window; buys upside participation in a stabilization scenario while limiting damage if the market keeps discounting reimbursement risk. Prefer 60-90 day tenor to capture a potential post-earnings squeeze.
• Pair trade: long BSX / short a higher-multiple medtech peer with more sentiment-sensitive growth expectations over the next 1-2 quarters. The idea is to isolate valuation normalization in BSX while reducing sector beta if healthcare multiple compression resumes.
• If you already own BSX, sell downside puts instead of adding common; the buyback authorization and valuation floor improve premium capture, but only if you’re comfortable owning through another volatility event.